Sofosbuvir — Hepatitis C Treatment

Sofosbuvir is an innovative direct-acting antiviral (DAA) agent, which is a nucleotide analog that inhibits the NS5B RNA polymerase of the hepatitis C virus (HCV). The drug became a revolutionary solution in hepatology, enabling a transition from interferon-based regimens to entirely oral therapy with unprecedentedly high cure rates.

The mechanism of action of sofosbuvir is based on its ability to act as a false substrate for the NS5B viral polymerase. Upon entering hepatocytes, the drug undergoes intracellular metabolism to form an active triphosphate. This metabolite is incorporated into the building HCV RNA strand, causing immediate chain termination and halting viral replication. Due to its high specificity for viral enzymes, sofosbuvir exhibits minimal toxicity to human cells.

The drug is effective against all major HCV genotypes (1–6). Sofosbuvir possesses a high genetic barrier to the development of resistance, making it a foundational component of most modern combined antiviral therapy regimens.

Wikipedia page

Indications

Sofosbuvir is used for the treatment of chronic hepatitis C as part of comprehensive therapy regimens:

Chronic Hepatitis C (Genotypes 1, 2, 3, 4, 5, 6): treatment of adult patients and pediatric patients (aged 3 years and older) in combination with other antiviral agents.
Patients with Cirrhosis: therapy for individuals with compensated or decompensated liver cirrhosis (in combination with ribavirin).
HIV/HCV Co-infection: treatment of patients simultaneously infected with human immunodeficiency virus and hepatitis C.
Transplant Waitlist: prevention of HCV reinfection after liver transplantation in patients with hepatocellular carcinoma.

Dosage and administration

The sofosbuvir administration regimen is typically standardized and depends on the specific combination of drugs used.

Standard Dose: 400 mg (one tablet) once daily.
Administration Rules: the tablet should be taken with food and swallowed whole (it has a very bitter taste, so chewing is not recommended).
Duration of Course: usually 12 or 24 weeks, depending on the viral genotype and the degree of liver damage (presence of cirrhosis).
Missed Dose: if less than 18 hours have passed since the missed dose, it should be taken immediately. If more than 18 hours, wait for the next scheduled dose.
Vomiting: if vomiting occurs within 2 hours of administration, an additional tablet should be taken.

The use of sofosbuvir is restricted in the following clinical situations:

Monotherapy: sofosbuvir is never used alone; it is only effective in combination with other medications.
Co-administration with Amiodarone: there is a risk of severe, life-threatening bradycardia (slowing of the heart rate).
Drug Interactions: administration with potent P-glycoprotein inducers (rifampin, St. John's wort, carbamazepine) is contraindicated as they significantly reduce treatment efficacy.
Severe Renal Impairment: (caution is required in some cases, although modern guidelines have expanded its use).
Pediatric Use: safety and efficacy have not been established in children under 3 years of age.

Sofosbuvir is generally well-tolerated; most side effects are associated with other drugs in the regimen (ribavirin or interferon):

General Symptoms: fatigue, headache, and dizziness.
Gastrointestinal Tract: nausea, decreased appetite, and occasionally dry mouth.
Nervous System: insomnia and mild irritability.
Laboratory Parameters: possible increase in bilirubin levels or decrease in hemoglobin levels (especially when combined with ribavirin).
Skin Reactions: pruritus or dry skin may occur very rarely.

Frequently Asked Questions

Sofosbuvir is a pangenotypic inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. The substance acts as a "decoy" for the virus: it incorporates itself into the growing viral RNA strand, leading to immediate chain termination. This effectively blocks the virus's ability to replicate within liver cells.

No, sofosbuvir should not be used as monotherapy. To prevent the virus from developing resistance, it is always used in combination with other active substances (such as ledipasvir, velpatasvir, or daclatasvir). The choice of combination depends on the viral genotype and the patient's liver condition.

Sofosbuvir is taken as one tablet (typically 400 mg) once daily. It is crucial to follow a strict schedule and not miss doses to maintain a consistent concentration of the substance in the blood. The tablet should be swallowed whole (due to its bitter taste), preferably with food.

Taking sofosbuvir along with amiodarone (a drug used to treat heart rhythm disorders) can lead to severe, life-threatening bradycardia (a dangerously slow heart rate). This combination is strictly contraindicated. Patients taking any cardiac medications must inform their doctor before starting therapy.

The primary indicator of success is achieving SVR (Sustained Virologic Response). This means the hepatitis C virus is not detected in the blood using a high-sensitivity PCR test 12 or 24 weeks after completing the treatment course. Modern regimens based on sofosbuvir offer cure rates exceeding 95% in most cases.